---
title: "ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/286821171.md"
description: "ImmunityBio has secured exclusive U.S. rights to the Tokyo-172 BCG strain through a supply agreement with Japan BCG Laboratory. The agreement allows ImmunityBio to develop, conduct clinical trials, and manage regulatory approvals for 10 years post-FDA approval, with no upfront payments required. After approval, ImmunityBio must purchase at least two batches annually. The deal also includes rights for certain ex-U.S. territories."
datetime: "2026-05-18T21:23:00.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/286821171.md)
  - [en](https://longbridge.com/en/news/286821171.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/286821171.md)
---

# ImmunityBio Secures Exclusive U.S. Rights to Tokyo-172 BCG in Supply Pact With Japan BCG Laboratory

ImmunityBio entered an exclusive development and supply agreement with Japan BCG Laboratory to manufacture and supply the Tokyo-172 strain of BCG for the United States and its territories. ImmunityBio will handle development, clinical trials, and U.S. regulatory approvals, and will have exclusive rights to purchase, import, sell, and distribute the product for 10 years from FDA approval. No payments are due before approval, with regulatory submission vials provided at no cost; after approval, ImmunityBio must purchase at least two batches annually. The deal includes a right of first negotiation for certain ex-U.S. territories and standard termination rights.

**Agreement details:**

-   **Agreement type**: Exclusive development and supply agreement for Tokyo-172 BCG in the U.S.
-   **Counterparty**: Japan BCG Laboratory
-   **Signed / Effective**: May 14 2026 / May 14 2026
-   **Duration / Termination**: 10 years from FDA approval
-   **Reason**: Secure exclusive U.S. supply of Tokyo-172 BCG

Original SEC Filing: ImmunityBio, Inc. \[ IBRX \] - 8-K - May. 18, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)

## Related News & Research

- [ImmunityBio Expands Bladder Cancer Arsenal With Exclusive Japanese BCG Partnership](https://longbridge.com/en/news/286787574.md)
- [10:24 ETIBRX INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of Securities Class Action Deadline on May 26, 2026](https://longbridge.com/en/news/286432680.md)
- [Lantern Pharma raises capital, plans AI platform spinoff](https://longbridge.com/en/news/286480334.md)
- [Alkermes reports encouraging data from Phase III study of Lumryz](https://longbridge.com/en/news/286349759.md)
- [Analyst Reiterates Buy on Corbus, Maintains $38 Price Target on CRB-701 Oncology Potential](https://longbridge.com/en/news/286284525.md)